AiPBAND

What AiPBAND does

AiPBAND (An Integrated Platform for Developing Brain Cancer Diagnostic Techniques) is an EU-funded Marie Skłodowska-Curie Actions Innovative Training Network that ran from January 2018 to December 2021 under Horizon 2020 grant agreement 764281, coordinated by the University of Plymouth. It is not a commercial company but a time-limited research training consortium that trained 14 Early Stage Researchers across 9 academic and 3 non-academic beneficiaries in 5 EU member states, focused on the early diagnosis of gliomas — brain tumours affecting approximately 25,000 people annually in Europe and responsible for the majority of primary brain tumour deaths.

The project's technical scope is an integrated diagnostic platform built around three multiplex biosensor modalities (plasmonic-based, graphene-based, and digital ELISA assay-based, plus EGOFET sensors), the GlioBase glioblastoma multiforme biomarker knowledge database, a Big Sensing Intelligent Warehouse for multi-omics data, and a cloud-based diagnostic system. Machine learning techniques (SDAE/VAE for multi-omics dimensionality reduction, statistical biomarker discovery, GANs for synthetic health data) are applied across biomarker identification and data infrastructure layers.

AiPBAND had no commercial revenue model. Its sole funding stream was the EUR 3,687,311.88 EU contribution, with allocation across consortium beneficiaries. Distribution occurred via academic publications, network training events, an annual conference series, and partner training in IP, technology transfer, and clinical research (ICH-GCP). The project has formally concluded; outputs and the website remain accessible, but no follow-on commercialization vehicle, successor grant, or spin-out entity has been disclosed in the available data.

Name

AiPBAND

Legal name

AiPBAND (An Integrated Platform for Developing Brain Cancer Diagnostic Techniques)

Website

https://aipband-itn.eu

Company type

Private

Founded year

2018

Operating status

Closed

Headcount range

11–50 employees

Short description

AiPBAND was an EU Horizon 2020 MSCA-ITN research training network (2018-2021) coordinated by the University of Plymouth, training 14 early-stage researchers across 12 European beneficiaries to develop biosensor-based, big-data-enabled diagnostic techniques for early detection of gliomas.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics Research

NAICS

Medical Laboratories (621511), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Proteomics & Mass Spectrometry Services (HLAGANAB)

akta.pro secondary industries

Model Development & Training Platforms (AutoML, Notebooks, Feature Stores) (HDAEANAB), AI/ML Solution Integration & MLOps Enablement (BPAEAAAJ), Model Serving, Inference & Deployment Platforms (APIs, Edge/On-Prem) (HDAEANAC)

Keywords

• Brain cancer diagnostics
• Biosensor research
• Medical diagnostics innovation
• Bioinformatics platforms
• Research training networks

Headquarters

HQ city

Plymouth

HQ country

United Kingdom

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. EU Research Funding (H2020 MSCA-ITN): AiPBAND received EUR 3,687,311.88 in funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 764281. The project runs from January 1, 2018 to December 31, 2021.

Go-to-market motion1 record

Marketing channels4 records

Core offering

AiPBAND is an EU-funded Marie Skłodowska-Curie Innovative Training Network (MSCA-ITN) that develops integrated diagnostic technologies for brain cancer, including plasmonic biosensors, graphene biosensors, and digital ELISA biosensors. The project builds supporting data infrastructure such as the GlioBase database, the Big Sensing Intelligent Warehouse, and a cloud-based diagnostic platform, while training early-stage researchers across European partner institutions.

Product overview

AiPBAND is a research training network (not a commercial company) developing an integrated diagnostic platform for brain cancer. The platform comprises multiple interconnected components: three types of multiplex biosensors (plasmonic-based, graphene-based, and digital ELISA assay-based) for biomarker detection; GlioBase, a GBM-specific biomarker knowledge database; a Big Sensing Intelligent Warehouse for multi-omics data; and a cloud-based diagnostic system. The platform is designed for clinical validation of biomarkers for glioma diagnosis, with early-stage researchers developing individual projects under this unified framework.

Differentiator

Problem solved

Functional benefit

Products and services

• Plasmonic biosensors Biosensor technology developed for brain cancer diagnostic applications, part of the integrated diagnostic platform research output of the AiPBAND network.
• Graphene biosensors Graphene-based biosensor technology developed for brain cancer diagnostic applications as part of the AiPBAND integrated diagnostic platform.
• Digital ELISA biosensors Digital ELISA (enzyme-linked immunosorbent assay) biosensor technology developed for brain cancer diagnostic applications within the AiPBAND integrated diagnostic platform.
• GlioBase database A specialized database supporting brain cancer biomarker and biosensing research, developed as part of the AiPBAND data infrastructure for consortium researchers.
• Big Sensing Intelligent Warehouse A large-scale data warehouse infrastructure supporting biosensing and diagnostic data management across the AiPBAND consortium.
• Cloud-based diagnostic platform A cloud-hosted diagnostic platform supporting brain cancer diagnostic workflows and integrated biosensor data analysis across the AiPBAND consortium.
• Early-Stage Researcher (ESR) Training Program Marie Skłodowska-Curie Innovative Training Network program providing research training to early-stage researchers (ESRs) in brain cancer diagnostic technologies across 9 academic and 3 non-academic beneficiaries in 5 EU member states.

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

17 partnerships are on record, tiered core and minor.

• University of PlymouthcoreStrategic or Co-development PartnerProject Coordinator. Host of project coordinator Dr Xinzhong Li and supervisors Prof Genhua Pan and Prof Shaofeng Liu. EU contribution: EUR 819,863.64.
• University College LondoncoreStrategic or Co-development PartnerAcademic beneficiary. Prof Sebastian Brandner (Professor of Neuropathology) is the contact. EU contribution: EUR 273,287.88.
• Imperial College LondoncoreStrategic or Co-development PartnerAcademic beneficiary. Prof Yi-Ke Guo (Professor of Computing Science) is the contact.
• Stockholm UniversitycoreStrategic or Co-development PartnerAcademic beneficiary. Prof Mats Nilsson (Professor of Molecular Diagnostics) is the contact. EU contribution: EUR 263,659.32.
• Karolinska InstitutetcoreStrategic or Co-development PartnerAcademic beneficiary. Prof Janne Lehtiö (Professor of Medical Proteomics) is the contact.
• University of CataniacoreStrategic or Co-development PartnerAcademic beneficiary. Prof Giuseppe Spoto (Professor of Analytical Chemistry) is the contact.
• Istituti Fisioterapici Ospitalieri (IRE)coreStrategic or Co-development PartnerResearch organization beneficiary. Dr Maria Giulia Rizzo is the contact. EU contribution: EUR 258,061.32.
• Prinses Maxima CentrumcoreStrategic or Co-development PartnerResearch organization beneficiary. Prof Henk Stunnenberg is the contact.
• KU LeuvencoreStrategic or Co-development PartnerAcademic beneficiary. Prof Jeroen Lammertyn (Professor of Bioscience Engineering) is the contact. EU contribution: EUR 250,560.
• Teesside UniversitycoreStrategic or Co-development PartnerAcademic beneficiary. Hosted Network Training Event NT-8.
• Scriba NanotecnologiecoreStrategic or Co-development PartnerPrivate for-profit entity beneficiary. Dr Pierpaolo Greco (Senior Application Scientist) is the contact.
• Medical Trials Analysis (MTA)coreImplementation/ SI/ Consulting PartnerPrivate for-profit entity (CRO) beneficiary providing clinical research training. Dr Cristina Morelli (Scientific Director) is the contact. Provides ICH-GCP certification training and e-learning platform access.
• The HyvecoreTechnology or IntegrationPrivate company beneficiary. Dr Marinel Cavelaars is the contact. Provides open source platform development and hosted NT-5 workshop. EU contribution: EUR 255,374.28.
• Engage - Key Technology Ventures AGminorGTM or Marketing PartnerPartner organization. Lars Krüger. Presented on technology transfer, IP management, and patent filing at NT-5 workshop.
• Universidad Autonoma de MadridminorStrategic or Co-development PartnerPartner organization. Alberto Martinez Serrano.
• Beijing Tian Tan HospitalminorStrategic or Co-development PartnerPartner organization. Liwei Zhang.
• Radboud UniversityminorStrategic or Co-development PartnerPartner organization.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Menarini Silicon Biosystems: Specializes in liquid biopsy through circulating tumor cell (CTC) capture and analysis. Comparable to AiPBAND in pursuing blood-based cancer diagnostics technology, though focused on CTC enumeration and single-cell analysis rather than biosensor-based molecular biomarker detection.
• Natera: Operates a molecular diagnostics business with a significant oncology liquid biopsy franchise (Signatera). Comparable to AiPBAND in developing blood-based molecular tests for cancer, though Natera is commercially deployed across multiple cancer indications.
• GRAIL: Pursues multi-cancer early detection from blood using methylation-based assays and next-generation sequencing. Comparable to AiPBAND's biomarker-plus-biosensor approach for cancer detection, with similar technical pillars (methylation biomarkers, ultra-sensitive detection, machine learning) but at commercial scale.
• Personal Genome Diagnostics (PGDx): Develops liquid biopsy and tissue-based genomic profiling kits for cancer diagnostics. Comparable to AiPBAND's mission of enabling non-invasive cancer detection through molecular biomarker analysis, though focused broadly on solid tumors rather than gliomas specifically.
• Guardant Health: A direct peer in blood-based cancer diagnostics, with commercial liquid biopsy products for therapy selection and recurrence monitoring. AiPBAND's goal of non-invasive blood-based brain tumor detection aligns directly with Guardant's liquid biopsy technology platform, though Guardant focuses on solid tumors beyond the CNS.

Emerging players

• Freenome: A multiomics platform combining genomics, epigenomics, and proteomics for early cancer detection from blood. Comparable to AiPBAND's multi-analyte biomarker detection strategy, though Freenome has reached commercial-stage clinical trials while AiPBAND remained at proof-of-concept.

Broad incumbents

• QIAGEN: A global leader in sample preparation and molecular diagnostics technologies for cancer and other diseases. Comparable to AiPBAND as a participant in the broader molecular diagnostics ecosystem that supports biomarker-based cancer detection, though operating at significantly larger scale across many indications.
• Foundation Medicine: A leader in cancer genomics diagnostics using both tissue and liquid biopsy approaches. Comparable to AiPBAND as it also pursues molecular profiling for cancer diagnosis, though it operates at commercial scale across multiple cancer types rather than focusing narrowly on gliomas.
• Bio-Techne: Provides proteomics research tools, reagents, and instruments used widely in academic and clinical biomarker discovery. Comparable to AiPBAND as a proteomics-adjacent business serving the same biomarker discovery workflows, particularly the proteomics-focused ESR work at Karolinska Institutet.
• Bio-Rad Laboratories: Manufactures life science research and clinical diagnostics instruments, including digital PCR (ddPCR) platforms used in molecular diagnostics. Comparable to AiPBAND's biosensor development efforts, particularly the digital ELISA on EWOD microfluidics work, though Bio-Rad's droplet partitioning technology serves many molecular biology workflows.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/aipband.itn
• Xx.com/aipband_itn
• LinkedInlinkedin.com/company/aipband

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AiPBAND